167 related articles for article (PubMed ID: 37249742)
1. Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia.
Chen J; Dong H; Fu R; Liu X; Xue F; Liu W; Chen Y; Sun T; Ju M; Dai X; Li H; Wang W; Chi Y; Yang R; Zhang L
J Thromb Thrombolysis; 2023 Aug; 56(2):291-300. PubMed ID: 37249742
[TBL] [Abstract][Full Text] [Related]
2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
3. Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
Kim KT; Sohn SI; Cho KH
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):913.e9-10. PubMed ID: 22305797
[TBL] [Abstract][Full Text] [Related]
4. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA; Zhu M; Zeidan AM; Wang R; Wang X; Davidoff AJ; Huntington SF; Giri S; Gore SD; Ma X
J Natl Compr Canc Netw; 2019 Mar; 17(3):211-219. PubMed ID: 30865915
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
6. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
7. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of essential thrombocythemia.
Gangat N; Tefferi A
Expert Opin Pharmacother; 2008 Jul; 9(10):1679-85. PubMed ID: 18570601
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
11. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Barbui T; Finazzi G
Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Passamonti F; Cazzola M
Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
[No Abstract] [Full Text] [Related]
13. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan.
Baba T; Hashimoto Y; Yasuda H; Araki M; Edahiro Y; Morishita S; Ochiai T; Shirane S; Ando J; Komatsu N
Hematology; 2022 Dec; 27(1):157-166. PubMed ID: 35068369
[TBL] [Abstract][Full Text] [Related]
14. Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.
Latagliata R; Rago A; Spadea A; Santoro C; Carmosino I; Breccia M; Napoleone L; Fama A; Biondo F; Volpicelli P; Vozella F; Stefanizzi C; Petti MC; Alimena G; Mazzucconi MG
Int J Hematol; 2009 Nov; 90(4):486-491. PubMed ID: 19701677
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
16. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Alvarez-Larrán A; Cervantes F; Pereira A; Arellano-Rodrigo E; Pérez-Andreu V; Hernández-Boluda JC; Ayats R; Salvador C; Muntañola A; Bellosillo B; Vicente V; Hernández-Nieto L; Burgaleta C; Xicoy B; Besses C
Blood; 2010 Aug; 116(8):1205-10; quiz 1387. PubMed ID: 20508163
[TBL] [Abstract][Full Text] [Related]
17. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
18. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
20. An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
Adam R; Priglinger M; Harrington T; Gottlieb D; Krause M
J Stroke Cerebrovasc Dis; 2014; 23(5):e373-4. PubMed ID: 24582788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
